Oncolytic Herpes Simplex Viruses as a Paradigm for the Treatment of Cancer

被引：33

作者：

Bommareddy, Praveen K. ^{[1
]}

Peters, Cole ^{[2
,3
,4
]}

Saha, Dipongkor ^{[2
,3
]}

Rabkin, Samuel D. ^{[2
,3
]}

Kaufman, Howard L. ^{[1
]}

机构：

[1] Rutgers Canc Inst New Jersey, Dept Surg, New Brunswick, NJ 08903 USA

[2] Massachusetts Gen Hosp, Dept Neurosurg, Mol Neurosurg Lab, Boston, MA 02114 USA

[3] Harvard Med Sch, Boston, MA 02114 USA

[4] Harvard Med Sch, Program Virol, Boston, MA 02115 USA

来源：

ANNUAL REVIEW OF CANCER BIOLOGY, VOL 2 | 2018年 / 2卷

关键词：

oncolytic viruses; immunotherapy; immuno-virotherapy; T-VEC; melanoma; HSV; NF-KAPPA-B; ADAPTIVE IMMUNE-RESPONSES; DENDRITIC CELLS; PROTEIN-SYNTHESIS; TALIMOGENE LAHERPAREPVEC; INTERFERON-PRODUCTION; GAMMA(1)34.5 PROTEIN; ANTITUMOR EFFICACY; MALIGNANT GLIOMAS; SIGNALING PATHWAY;

D O I：

10.1146/annurev-cancerbio-030617-050254

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Oncolytic viruses are native or modified viruses that directly kill tumor cells but spare normal tissue and promote host antitumor immunity. Recently, an oncolytic herpes simplex virus (oHSV) type 1-encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF) demonstrated significant clinical benefit in a randomized phase III clinical trial for patients with advanced melanoma, leading to regulatory approval in 2015. In this review, we provide a general characterization of herpes simplex viruses and discuss methods for vector modification, which can help limit viral pathogenicity and immunogenicity while promoting antitumor immunogenicity. We also provide insight into general strategies for using oHSV agents in tumor immunotherapy regimens for the treatment of cancer and briefly review some of the currently emerging preclinical and clinical data that support an important role for such agents in the treatment of cancer.

引用

页码：155 / 173

页数：19

共 173 条

[1] Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1 [J].

Advani, S. J. ;

Markert, J. M. ;

Sood, R. F. ;

Samuel, S. ;

Gillespie, G. Y. ;

Shao, M. Y. ;

Roizman, B. ;

Weichselbaum, R. R. .

GENE THERAPY, 2011, 18 (11) :1098-1102

[2] Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16 [J].

Aghi, M. ;

Visted, T. ;

DePinho, R. A. ;

Chiocca, E. A. .

ONCOGENE, 2008, 27 (30) :4249-4254

[3] Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication [J].

Aghi, M ;

Rabkin, S ;

Martuza, RL .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (01) :38-50

[4] Innate immune response of the human host to exposure with herpes simplex virus type 1: In vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction [J].

Ahmad, A ;

Sharif-Askari, E ;

Fawaz, L ;

Menezes, J .

JOURNAL OF VIROLOGY, 2000, 74 (16) :7196-7203

[5] Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus protein ICP47 [J].

Ahn, K ;

Meyer, TH ;

Uebel, S ;

Sempe, P ;

Djaballah, H ;

Yang, Y ;

Peterson, PA ;

Fruh, K ;

Tampe, R .

EMBO JOURNAL, 1996, 15 (13) :3247-3255

[6] Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry [J].

Akhtar, Jihan ;

Shukla, Deepak .

FEBS JOURNAL, 2009, 276 (24) :7228-7236

[7] NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors [J].

Alvarez-Breckenridge, Christopher A. ;

Yu, Jianhua ;

Price, Richard ;

Wojton, Jeffrey ;

Pradarelli, Jason ;

Mao, Hsiaoyin ;

Wei, Min ;

Wang, Yan ;

He, Shun ;

Hardcastle, Jayson ;

Fernandez, Soledad A. ;

Kaur, Balveen ;

Lawler, Sean E. ;

Vivier, Eric ;

Mandelboim, Ofer ;

Moretta, Alessandro ;

Caligiuri, Michael A. ;

Chiocca, E. Antonio .

NATURE MEDICINE, 2012, 18 (12) :1827-+

[8] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[9] Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma [J].

Andtbacka, Robert H. I. ;

Agarwala, Sanjiv S. ;

Ollila, David W. ;

Hallmeyer, Sigrun ;

Milhem, Mohammed ;

Amatruda, Thomas ;

Nemunaitis, John J. ;

Harrington, Kevin J. ;

Chen, Lisa ;

Shilkrut, Mark ;

Ross, Merrick ;

Kaufman, Howard L. .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 (12) :1752-1758

[10]

[Anonymous], 2017, J VIROL, DOI DOI 10.1128/JVI

← 1 2 3 4 5 6 7 8 9 10 →